After breast cancer: Implications for long-term primary care

Postgraduate Medicine

Volumn 105, Issue 6, 1999, Pages 103-112

  Ritter, Nathan ^a   Love, Neil ^a   Osman, Daniel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN CITRATE;

ADULT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER SCREENING; CASE REPORT; CONFERENCE PAPER; FEMALE; FERTILITY; HUMAN; LONG TERM CARE; MENOPAUSE; PREGNANCY; PRIMARY MEDICAL CARE; RECURRENT DISEASE; SEXUAL FUNCTION;

EID: 0033563075     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.1080/00325481.1999.11444925     Document Type: Conference Paper

References (19)

1. American Society of Clinical Oncology. Recommended breast cancer surveillance guidelines. J Clin Oncol 1997;15(5):2149-56
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451-67
3. Delozier T, Switsers O, Genot JY, et al. Efficacy of delayed adjuvant tamoxifen (TAM) in early breast cancer: a multicenter randomized trial. Proc Annu Meet Am Soc Clin Oncol 1993:A47
4. Olsen MR, Love RR. Delayed "adjuvant" tamoxifen therapy in postmenopausal women: ten-year results from the Wisconsin Tamoxifen Study. Proc Annu Meet Am Soc Clin Oncol 1998:A453
5. Prior P, Waterhouse JA. Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br J Cancer 1978;37(4):620-34
6. Mamounas EP, Bryant J, Fisher B, et al. Primary breast cancer as a risk factor for subsequent contralatetal breast cancer (CBC): NSABP experience from nine randomized trials. (Abstr) Breast Cancer Res Treat 1998;50(3):230
7. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18):1371-88
8. Assikis VJ, Jordan VC. Risks and benefits of tamoxifen therapy. Oncology (Huntingt) 1997;11(2 Suppl 1):21-3
9. Bertolissi A, Cartei G, Turrin D, et al. Behaviour of vaginal epithelial maturation and sex hormone binding globulin in postmenopausal breast cancer patients during the first year of tamoxifen therapy. Cytopathology 1998;9(4):263-70
10. Dorval M, Maunsell E, Deschenes L, et al. Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 1998;16(2):487-94
11. Dow KH, Ferrell BR, Leigh S, et al. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat 1996;39(3):261-73
12. DiSaia PJ, Grosen EA, Odicino F, et al. Replacement therapy for breast cancer survivors: a pilot study. Cancer 1995;76(10 Suppl):2075-8
13. Cobleigh MA. Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res 1998;94:209-30
14. Marsen J, Thirlaway K, West A, et al. The effect of tamoxifen on the sexual activity of breast cancer patients and the impact of HRT. (Abstr) Breast Cancer Res Treat 1998;50(3):269
15. Bachmann GA. Nonhormonal alternatives for the management of early menopause in younger women with breast cancer. J Natl Cancer Inst Monogr 1994;(16):161-7
16. Collichio FA, Agnello R, Staltzer J. Pregnancy after breast cancer: from psychosocial issues through conception. Oncology (Huntingt) 1998;12(5):759-65, 769; discussion 770, 773-5
17. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer 1998;83(12 Suppl American):2776-81
18. Brennan MJ, Miller LT. Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Cancer 1998;83(12 Suppl American):2821-7
19. Földi E. The treatment of lymphedema. Cancer 1998;83(12 Suppl American):2833-4